People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other, Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Direct Vet Marketing, Inc. | — | Other | Series D+ | $292.6M | $3.9B | 2013 |
| Morphic Holding, Inc. | — | Biotechnology | Series C | $200.6M | $1.5B | 2016 |
| KALA BIO, Inc. | — | Biotechnology | Series C | $158.8M | $8.3M | 2010 |
| Genocea Biosciences, Inc. | — | Biotechnology | Series C | $153.6M | $3.0B | 2010 |
| Chroma Medicine, Inc. | — | Biotechnology | Series D+ | $135.0M | $2.4B | 2023 |
| Editas Medicine, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.9B | 2015 |
| Visterra, Inc. | — | Biotechnology | Series B | $82.4M | $1.4B | 2009 |
| Navitor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $68.2M | $686.4M | 2020 |
| Renasant Bio, Inc. | — | Biotechnology | Series B | $55.5M | $144.0M | 2024 |
| Judo Bio Inc. | — | Biotechnology | Series B | $55.0M | $172.2M | 2022 |
| Akero Therapeutics, Inc. | — | Pharma | Series C | $45.5M | $1.6B | 2018 |
| Taris Biomedical Inc | — | Biotechnology | Series B | $36.9M | $535.8M | 2009 |
| Kinaset Therapeutics, Inc. | — | Pharmaceuticals | Series B | $30.0M | $438.1M | 2020 |
| Follica, Inc | — | Pharmaceuticals | Series A | $15.2M | $4.2M | 2010 |
| Remix Therapeutics, Inc. | — | Biotechnology | Series A | $13.7M | $93.0M | 2023 |
Kevin Bitterman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kevin Bitterman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 2 | 36 |
| Alan Crane | 2 | 9 |
| ROBERT PAULL | 2 | 4 |
| Mark Iwicki | 2 | 4 |
| Katrine Bosley | 2 | 4 |
| Vic Myer | 2 | 3 |
| Edward Kania | 2 | 2 |
| Asish Xavier | 1 | 18 |
| Ali Behbahani | 1 | 17 |
| Jean-Francois Formela | 1 | 17 |
| LEON CHEN | 1 | 15 |
| Michael Greeley | 1 | 15 |
| BIHUA CHEN | 1 | 14 |
| Amir Nashat | 1 | 14 |
| DAVID SHAW | 1 | 12 |
| William Clark | 1 | 12 |
| Michael Kelly | 1 | 11 |
| Brian Gallagher | 1 | 11 |
| Michael Higgins | 1 | 9 |
| Peter Smith | 1 | 9 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.